Glutathione and Function in HIV Patients
Completed · Phase 1
Conditions studied: HIV Infection, Erythrocyte Glutathione Deficiency
In brief
We have recently reported that older patients with HIV are deficient in glutathione (GSH) due to decreased availability of cysteine and glycine, and that oral supplementation with cysteine (as n-acetylcysteine) and glycine for 2-weeks corrects their own levels, and improves (but does not fully normalize) concentrations of red-cell GSH. We also found that when GSH deficient, subjects had impaired mitochondrial fuel oxidation and this improved with an increase in intracellular GSH concentrations. These older HIV patients also had significant increases in muscle strength with improvement of GSH levels.The current proposal in older HIV patients will investigate study if cysteine and glycine supplementation for a duration of 12 weeks will result in changes in : (a) GSH levels; (b) body composition/anthropometry; (c) strength and function; (d) quality of life; (e) mitochondrial energetics; (f) biochemistry (including dyslipidemia and oxidative stress); (g) protein and glucose metabolism; (h) cognition and memory. After completing supplementation for 3 months, GSH concentrations, strength, function, mitochondrial energetics and neurocognitive tests will be measured for a further 2 months to determine the effects of washout.
Key facts
- Study ID
- NCT02348775
- Run by
- Baylor College of Medicine
- People needed
- 16
- Starts
- 2014-11-01
- Expected to finish
- 2020-08-01
- Last updated by the study team
- 2021-02-21
Who can join
Age: 45 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- HIV patients:
- age 45-65 years
- Non-HIV subjects:
- age 45-65 years
You may not qualify if…
- Hospitalization in the past 3 months
- Untreated hypothyroidism or hyperthyroidism
- Known diabetes mellitus, hypercortisolemia, coronary artery disease.
- Known liver impairment (ALT and AST >2ULN)
- Renal impairment (Creatinine>1.4)
- Inability to walk
- Patients on anticoagulation or antiplatelet therapy.
- Patient with triglyceride concentrations >500 mg/dl.
Where it is running
- Baylor Metabolic Research Unit (MRU) — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.